- €20.66bn
- €53.04bn
- €46.61bn
- 37
- 65
- 63
- 56
Annual income statement for Bayer AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 41,400 | 44,081 | 50,739 | 47,637 | 46,606 |
Cost of Revenue | |||||
Gross Profit | 22,262 | 27,265 | 30,868 | 27,888 | 25,336 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 57,569 | 40,728 | 43,727 | 47,025 | 46,677 |
Operating Profit | -16,169 | 3,353 | 7,012 | 612 | -71 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -17,250 | 2,046 | 4,670 | -1,621 | -2,334 |
Provision for Income Taxes | |||||
Net Income After Taxes | -15,561 | 1,022 | 4,166 | -2,942 | -2,546 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -10,495 | 1,000 | 4,150 | -2,941 | -2,552 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -10,495 | 1,000 | 4,150 | -2,941 | -2,552 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.25 | 4.39 | 8.12 | 6.41 | 2.04 |
Dividends per Share |